As DNMT inhibitors have been approved for patient treatment, our study thus prompts immediate clinical trial evaluation of these inhibitors, alone or in combination, in cancer patients exhibiting ASCT2/glutamine addiction. The gene discussed is DNMT1; the disease is cancer.